Vaccine Info

Cervavac HPV Vaccine

Authored by
Last reviewed
January 25, 2023
Fact checked by
Robert Carlson, MD

Cervavac HPV Vaccine

Serum Institute of India (SII) Cervavac is the first quadrivalent human papillomavirus (qHPV) vaccine made in India, protecting people against HPV types 6, 11, 16, and 18. Cervavac efficacy was studied in HPV vaccine clinical trials that started in September 2018.  

The Drugs Controller General of India (DCGI) granted market authorization to the Pune-based Serum Institute of India (SII) to manufacture the CervaVac vaccine in 2021. In the application to the DCGI, SII stated that Cervavac had demonstrated a robust antibody response higher than the baseline against all targeted HPV types and in all doses and age groups.

The Lancet Oncology published an Editorial on October 1, 2022, HPV vaccination in south Asia: new progress, old challenges. A myriad of factors, including poor awareness of cervical cancer, low screening uptake, insufficient availability of and access to vaccines, and screening and vaccine reluctance, all contribute to the high burden of disease in the region, as we highlighted in a 2019 Editorial

Pune-based Serum Institute of India is now the world's largest vaccine manufacturer by the number of doses produced and sold globally (more than 1.5 billion doses), which includes Polio vaccine, Diphtheria, Tetanus, Pertussis, Hib, BCG, r-Hepatitis B, Measles, Mumps, Rubella as well as Pneumococcal and Covid-19 vaccines. 

Cervavac Price

Adar Poonawalla, CEO of SSI, stated: The Cervavac vaccine price range would be Rs 200-400, making it an affordable HPV vaccine.

Cervavac Availability 2023

The Cervavac vaccine became available in India on January 24, 2023, with an international launch scheduled for 2024.

Cervavac Indication

Cervical cancer is the most common HPV-related disease in women. In India, cervical cancer is the second-most common cancer, especially among women between 15 and 44 years of age. Every year 122,844 Indian women are diagnosed with cervical cancer, and 67,477 die from the disease, according to figures from 2012, says NHP.

In 2021, the International Taskforce on Cervical Cancer Elimination in the Commonwealth was launched by the Commonwealth Secretariat (May/2021) and the Union for International Cancer Control to step up efforts towards preventing and treating cervical cancer to align with WHO's Global Strategy (Nov/2020) to accelerate the elimination of cervical cancer as a public health problem. 

Additional HPV vaccine information is posted at

Cervavac Vaccine News 2022

January 24, 2023 - The SII launched the first indigenously developed HPV vaccine against cervical cancer in women. 

October 21, 2022 - Serum Institute of India will start supplying small quantities of the CervaVac vaccine to the Indian government in early 2023.

October 1, 2022 - The peer-review journal The Lancet published an Editorial - HPV vaccination in south Asia: new progress, old challenges.

September 1, 2022 - News article: Serum Institute's qHPV vaccine is a game changer.

September 1, 2022 - Announcing the scientific completion of the quadrivalent Human Papilloma Virus (qHPV) vaccine in the presence of Mr. Adar C. Poonawalla, CEO, Serum Institute of India, Pune, and other prominent scientists and dignitaries, Dr. Jitendra Singh said, this affordable and cost-effective vaccine marks an essential day for DBT and BIRAC as it takes India a step closer to PM Modi's vision of Atmanirbhar Bharat.

July 18, 2022 - The Serum Institute of India received regulatory approval to sell an indigenously developed HPV vaccine that can prevent cervical cancer. The Drugs Controller General of India granted market authorization for the Quadrivalent Human Papillomavirus vaccine (qHPV). 

June 15, 2022 - ANI reported the Drugs Controller General of India's Subject Expert Committee recommended granting market authorization to the Serum Institute of India to manufacture India's indigenously-developed CERVAVAC Quadrivalent Human Papillomavirus vaccine (qHPV).

Cervavac Vaccine Clinical Trials

Serum Institute of India applied for market authorization after completing the phase 2/3 clinical trial with the support of the Department of Biotechnology to ensure its early availability in the country," said the sources.

Clinical Trials

No clinical trials found